易黄汤联合重组人干扰素治疗宫颈高危型人乳头瘤病毒感染临床研究

Clinical Study on Yihuang Decoction Combined with Recombinant Interferon for Cervical High-Risk Human Papilloma Virus Infection

目的:观察易黄汤联合重组人干扰素治疗宫颈高危型人乳头瘤病毒(HR-HPV)感染的疗效及对病毒载量的影响。方法:回顾性选取宫颈HR-HPV感染患者100例,依据治疗方法不同分为研究组和对照组各50例。对照组给予重组人干扰素治疗,研究组在对照组基础上给予易黄汤口服,2组均治疗2个月经周期。评价2组临床疗效,比较2组治疗前后中医证候评分、HPV转阴情况、HR-HPV病毒载量及不良反应发生情况。结果:研究组总有效率为92.00%,高于对照组76.00%(P<0.05)。治疗前,2组各项中医证候评分及总分比较,差异无统计学意义(P>0.05)。治疗后,2组各项中医证候评分及总分低于治疗前(P<0.05),且研究组各项中医证候评分及总分低于对照组(P<0.05)。研究组治疗后3个月、6个月、1年HPV转阴率均高于对照组(P<0.05)。治疗前,2组HR-HPV病毒载量比较,差异无统计学意义(P>0.05)。治疗后,2组HR-HPV病毒载量较治疗前降低(P<0.05),且研究组HR-HPV病毒载量低于对照组(P<0.05)。研究组不良反应发生率为4.00%,低于对照组20.00%(P<0.05)。结论:易黄汤联合重组人干扰素治疗宫颈HR-HPV感染疗效显著,可以改善患者临床症状,降低病毒载量,促进HPV转阴,降低不良反应发生率。

Objective:To observe the curative effect of Yihuang Decoction combined with recombinant interferon for cervical high-risk human papilloma virus(HR-HPV) infection and its effect on viral load.Methods:A total of 100 cases of patients with cervical HR-HPV infection were retrospectively selected and divided into the study group and the control group according to different treatment methods,with 50 cases in each group respectively. The control group was treated with recombinant interferon,and the study group was additionally given the oral administration of Yihuang Decoction based on the treatment of the control group. Both groups were treated for 2 menstrual cycles. The clinical effects in the two groups were evaluated. The traditional Chinese medicine(TCM) syndrome scores,the negative conversion of HPV,the viral load of HR-HPV and the incidence of adverse reactions before and after treatment in the two groups were compared. Results: The total effective rate was 92.00% in the study group, higher than that of76.00% in the control group(P<0.05). Before treatment,there was no significant difference being found in the comparison of the scores of TCM syndromes and the total scores between the two groups(P>0.05).After treatment,the scores of TCM syndromes and the total scores in the two groups were lower than those before treatment(P<0.05),and the scores of TCM syndromes and the total score in the study group were lower than those in the control group(P<0.05). The negative conversion rates of HPV in 3 months,6 months and one year after treatment in the study group were higher than those in the control group(P<0.05). Before treatment,there was no significant difference being found in the comparison of viral load of HR-HPV between the two groups(P>0.05). After treatment,the viral load of HR-HPV in the two groups was decreased when compared with that before treatment(P<0.05),and the viral load of HR-HPV in the study group was lower than that in the control group(P<0.05). The incidence of adverse reactions was4.00% in the study group,lower than that of 20.00% in the control group(P<0.05). Conclusion:Yihuang Decoction combined with recombinant interferon has a significant curative effect in the treatment of cervical HR-HPV infection,which can improve the clinical symptoms of patients,decrease the viral load,promote the negative conversion of HPV,and reduce the incidence of adverse reactions.